Type beta transforming growth factor (β-TGF) is a potent regulator of cell growth and differentiation. The human glioblastoma cell line, T-MGl, was growth inhibited by β-TGF under anchorage independent conditions. The antiproliferative effect of β-TGF was potentiated to nearly total arrest by low doses of retinoic acid (RA) or tumor necrosis factor (TNF), while epidermal growth factor, platelet-derived growth factor, interleukin-2, and gamma interferon did not have this potentiating effect. The potentiation of the β-TGF effect by RA and TNF could not be explained by modulation of the epidermal growth factor receptor, the β-TGF receptor, or the TNF receptor. β-TGF alone and in combination with RA or TNF were further tested on primary cultures from freshly resected human glioma biopsies (n=13). There was great individual variation in sensitivity to β-TGF, RA, or TNF. The astrocytoma and oligodendroglioma cells were inhibited to various degrees by β-TGF or TNF, while most of the glioblastomas were not sensitive to these agents. Most of the biopsies were stimulated by RA. RA or TNF did not potentiate the growth inhibitory effect of β-TGF on biopsy cells. We therefore think it unlikely that β-TGF in combination with RA or TNF will be effective agents in the treatment of gliomas.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Assoian RK, Frolik CA, Roberts AB, Miller DM, Sporn MB (1984) Transforming growth factor-beta controls receptor levels for epidermal growth factor in NRK fibroblasts. Cell 36:35–41
Bigner DD, Schold C, Bigner SH, Bullard DE, Wickstrand C (1981) How heterogeneous are gliomas? Cancer Treat Rep 65 (Suppl. 2):45–49
Fanger BO, Wakefield LM, Sporn MB (1986) Structure and properties of the cellular receptor for transforming growth factor type beta. Biochemistry 25:3083–3091
Ignotz RA, Massagué J (1985) Type beta transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts. Proc Natl Acad Sci 82:8530–8534
Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, AlvarezMon M, Derynck R, Sporn MB, Fauci AS (1986) Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163:1037–1050
Kleveland PM, Haugen SE, Waldum HL (1985) The preparation of bioactive 125I-gastrin using Iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol 20:569–576
Masui T, Wakefield LM, Lechner JF, LaVeck MA, Sporn MB, Harris CC (1986) Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Acad Sci 83:2438–2442
Moses HL, Tucker RF, Loef EB, Coffey RJ, Halper J, Shipley GD (1985) Type beta transforming growth factor is a growth stimulator and a growth inhibitor. In: Feramisco J, Ozanne B, Stiles C (eds) Cancer cells 3. Cold Spring Harbor Laboratory, Cold Spring Harbor NY, pp 65–71
Ristow H-J (1986) BSC-1 growth inhibitor/type beta transforming growth factor is a strong inhibitor of thymocyte proliferation. Proc Natl Acad Sci 83:5531–5533
Roberts AB, Sporn MB (1985) Transforming growth factors. Cancer Surveys 4:683–707
Roberts AB, Frolik CA, Anzano MA, Sporn MB (1983) Transforming growth factor from neoplastic and noneoplastic tissues. Fed Proc 42:2621–2626
Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB (1985) Type beta transforming growth factor: A bifunctional regulator of cellular growth. Proc Natl Acad Sci 82:119–123
Roberts AB, Roche NS, Sporn MB (1985) Selective inhibition of the anchorage-independent growth of myc-transfected fibroblasts by retinoic acid. Nature 315:237–239
Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS (1986) Effects of transforming growth factor beta on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136:3916–3920
Tucker RF, Shipley GD, Moses HL, Holley RW (1984) Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science 226:705–707
Unsgaard G, Larsen B, Dalen A, Vik R, Ringkjøb R (1985) A new technique to register proliferation of clonogenic cells from brain tumors. J Neuro-Oncol 3:203–209
Unsgaard G, Helseth E, Vik R, Dalen A (1988) An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2C, interferon gamma and tumor necrosis factor. Acta Neurochir (in press)
Wakefield LM, Smith DM, Masui T, Harris CC, Sporn MB (1987) Distribution and modulation of the cellular receptor for transforming growth factor-beta. J Cell Biol 105:965–975
van Zoelen EJJ, van Oostwaard TMJ, de Laat SW (1986) Transforming growth factor-beta and retinoic acid modulate phenotypic transformation of normal rat kidney cells induced by epidermal growth factor and platelet-derived growth factor. J Biol Chem 261:5003–5009
About this article
Cite this article
Helseth, E., Unsgaard, G., Dalen, A. et al. Effects of type beta transforming growth factor in combination with retinoic acid or tumor necrosis factor on proliferation of a human glioblastoma cell line and clonogenic cells from freshly resected human brain tumors. Cancer Immunol Immunother 26, 273–279 (1988). https://doi.org/10.1007/BF00199941
- Type beta transforming growth factor
- Tumor necrois factor
- Retionic acid